WOBURN, Mass., July 29, 2016 /PRNewswire-iReach/ -- On-demand production of biopharmaceuticals has been demonstrated in a Pharyx Corporation miniature cell culture system. In a paper published today in the journal Nature Communications, MIT scientists demonstrated on-demand biopharmaceutical production where either human growth hormone or interferon -- both used to speed-up wound healing - were produced depending on which nutrients were fed to genetically engineered yeast cells.
Photo - http://photos.prnewswire.com/prnh/20160727/393673
The Pharyx cell culture system operates up to four unique microbioreactors that are each the size of a deck of cards. The microbioreactors use integrated filters to retain the productive cells and realize automated fluid processing such as the rapid nutrient exchange that was used to switch between the production of human growth hormone or interferon. The microbioreactor was operated in continuous perfusion mode, where a high density of cells were retained within the microbioreactor to continuously convert the input flow of nutrients to an outflow of the therapeutic proteins.
The work at MIT was funded by the Defense Advanced Research Projects Agency (DARPA) as part of its Battlefield Medicine initiative with the goal of "developing a flexible, miniaturized synthesis and manufacturing platform, to enable distributed, on-demand medicine manufacturing capabilities in battlefield and other austere environments." DARPA's website states that ultimately, it is seeking to "enable effective small-batch pharmaceutical production that obviates the need for individual drug stockpiling, cold storage, and complex logistics."
Although the MIT project used the microbioreactor system for small-scale distributed biopharmaceutical production, the Pharyx microbioreactor system can be applied to any situation requiring small-scale continuous cultures, or where automated fluid exchanges are needed. Examples include optimizing perfusion cultures for mammalian cells producing monoclonal antibodies, microbiology R&D, and cell culture for personalized medicine.
Media Contact: Public Relations, Pharyx Corporation, 855-742-2763, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Pharyx Corporation
Advertisement
Photo - http://photos.prnewswire.com/prnh/20160727/393673
The Pharyx cell culture system operates up to four unique microbioreactors that are each the size of a deck of cards. The microbioreactors use integrated filters to retain the productive cells and realize automated fluid processing such as the rapid nutrient exchange that was used to switch between the production of human growth hormone or interferon. The microbioreactor was operated in continuous perfusion mode, where a high density of cells were retained within the microbioreactor to continuously convert the input flow of nutrients to an outflow of the therapeutic proteins.
Advertisement
The work at MIT was funded by the Defense Advanced Research Projects Agency (DARPA) as part of its Battlefield Medicine initiative with the goal of "developing a flexible, miniaturized synthesis and manufacturing platform, to enable distributed, on-demand medicine manufacturing capabilities in battlefield and other austere environments." DARPA's website states that ultimately, it is seeking to "enable effective small-batch pharmaceutical production that obviates the need for individual drug stockpiling, cold storage, and complex logistics."
Although the MIT project used the microbioreactor system for small-scale distributed biopharmaceutical production, the Pharyx microbioreactor system can be applied to any situation requiring small-scale continuous cultures, or where automated fluid exchanges are needed. Examples include optimizing perfusion cultures for mammalian cells producing monoclonal antibodies, microbiology R&D, and cell culture for personalized medicine.
Media Contact: Public Relations, Pharyx Corporation, 855-742-2763, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Pharyx Corporation
